Risks of Testosterone for Postmenopausal Women.
Endocrinol Metab Clin North Am
; 50(1): 139-150, 2021 03.
Article
em En
| MEDLINE
| ID: mdl-33518182
ABSTRACT
Transdermal testosterone therapy, dosed within premenopausal physiologic testosterone ranges, used alone or with menopausal hormone therapy for postmenopausal hypoactive sexual desire disorder, has shown short-term efficacy, with few androgenic side effects. After natural or surgical menopause, meaningful improvements include an additional satisfying sexual episode per month; improvement in desire, arousal, orgasm, pleasure, and responsiveness; and a reduction in distress. Long-term data on cardiovascular, cancer, and cognitive safety are lacking. No approved testosterone preparation is available for women. Compounded testosterone creams or reduced dosing of male-approved therapies represent off-label use. Injections or pellets cause supraphysiological testosterone levels and are not recommended.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Testosterona
/
Disfunções Sexuais Psicogênicas
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article